0000000000760725
AUTHOR
Géraldine Jeudy
Unusual presentation of blastic plasmacytoid dendritic cell neoplasm: Pitfalls in other hematolymphoid neoplasms
Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare CD4+/CD56+ hematological malignancy with aggressive clinical course and poor prognosis. Histologically, BPDCN is characterized by a diffuse, monomorphous infiltration of cutaneous, subcutaneous, and sometimes other tissues such as lymph nodes and bone marrow, by medium-sized neoplastic cells with blastoid morphology. Typically, there is absence of lymphocytic infiltrate. Diagnosis relies on immunophenotypic expression of CD4, CD56, and the more specific markers of plasmacytoid dendritic cells CD123, CD303/BDCA2, and TCL1. We report a case of a 57-year-old man who presented a 4 cm-long solitary, erythemateous lesion on t…
Prospective Study of the Evolution of Blood Lymphoid Immune Parameters during Dacarbazine Chemotherapy in Metastatic and Locally Advanced Melanoma Patients
BackgroundThe importance of immune responses in the control of melanoma growth is well known. However, the implication of these antitumor immune responses in the efficacy of dacarbazine, a cytotoxic drug classically used in the treatment of melanoma, remains poorly understood in humans.MethodsIn this prospective observational study, we performed an immunomonitoring of eleven metastatic or locally advanced patients treated with dacarbazine as a first line of treatment. We assessed by flow cytometry lymphoid populations and their activation state; we also isolated NK cells to perform in vitro cytotoxicity tests.ResultsWe found that chemotherapy induces lymphopenia and that a significantly hig…
Effets secondaires thyroïdiens sous immunothérapie anti-PD1 : évaluation des facteurs de survenue
Objectifs L’utilisation des immunotherapies anti-PD1 dans le traitement des cancers de la peau et du poumon, s’accompagne d’effets secondaires auto-immuns thyroidiens. L’objectif de cette etude etait de determiner leur frequence et d’identifier les facteurs favorisant leur survenue. Methodes Etude retrospective chez 196 patients traites pour un melanome malin ou un cancer bronchique non a petites cellules (CBNPC) par pembrolizumab ou par nivolumab, entre juillet 2014 et fevrier 2018. Quarante-quatre patients ont ete exclus de l’etude (34 pour antecedents de dysthyroidie et 18 par manque de donnees). Les dysthyroidies sous anti-PD1 ont ete differenciees des modifications de TSH par surcharge…